Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Edoxaban for Cancer-Associated Venous Thromboembolism.

Nasser NJ.

N Engl J Med. 2018 Jul 5;379(1):94-5. doi: 10.1056/NEJMc1806646. No abstract available.

PMID:
29975033
2.

Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy.

Thor M, Jackson A, Zelefsky MJ, Steineck G, Karlsdòttir A, Høyer M, Liu M, Nasser NJ, Petersen SE, Moiseenko V, Deasy JO.

Radiother Oncol. 2018 Apr;127(1):88-95. doi: 10.1016/j.radonc.2018.02.020. Epub 2018 Mar 9.

PMID:
29530433
3.

Vitamin D ointment for prevention of radiation dermatitis in breast cancer patients.

Nasser NJ, Fenig S, Ravid A, Nouriel A, Ozery N, Gardyn S, Koren R, Fenig E.

NPJ Breast Cancer. 2017 Mar 31;3:10. doi: 10.1038/s41523-017-0006-x. eCollection 2017.

4.

Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer.

Nasser NJ, Thoms J, Soosaipillai A, Pintilie M, Wang R, Diamandis EP, Bristow RG.

Radiother Oncol. 2017 Sep;124(3):427-432. doi: 10.1016/j.radonc.2017.03.023. Epub 2017 Apr 17.

PMID:
28427756
5.

Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer.

Kundel Y, Nasser NJ, Rath-Wolfson L, Purim O, Yanichkin N, Brenner R, Zehavi T, Nardi Y, Fenig E, Sulkes A, Brenner B.

Am J Clin Oncol. 2018 Jun;41(6):613-618. doi: 10.1097/COC.0000000000000337.

PMID:
27740975
6.

Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.

Nasser NJ, Cohen GN, Dauer LT, Zelefsky MJ.

Brachytherapy. 2016 Jul-Aug;15(4):420-425. doi: 10.1016/j.brachy.2016.03.012. Epub 2016 May 12.

7.

Long-term outcome of magnetic resonance spectroscopic image-directed dose escalation for prostate brachytherapy.

King MT, Nasser NJ, Mathur N, Cohen GN, Kollmeier MA, Yuen J, Vargas HA, Pei X, Yamada Y, Zakian KL, Zaider M, Zelefsky MJ.

Brachytherapy. 2016 May-Jun;15(3):266-73. doi: 10.1016/j.brachy.2016.02.003. Epub 2016 Apr 20.

8.

Evaluation of the dosimetric impact of loss and displacement of seeds in prostate low-dose-rate brachytherapy.

Wang Y, Nasser NJ, Borg J, Saibishkumar EP.

J Contemp Brachytherapy. 2015 Jun;7(3):203-10. doi: 10.5114/jcb.2015.52127. Epub 2015 Jun 9.

9.

Dosimetric evaluation of clinical target volume in the postimplant analysis of low-dose-rate brachytherapy for prostate cancer.

Nasser NJ, Sappiatzer J, Wang Y, Borg J, Saibishkumar EP.

Brachytherapy. 2015 Mar-Apr;14(2):189-96. doi: 10.1016/j.brachy.2014.08.044. Epub 2014 Oct 7.

PMID:
25301338
10.

Pharmacokinetics of low molecular weight heparin in patients with malignant tumors.

Nasser NJ, Na'amad M, Weinberg I, Gabizon AA.

Anticancer Drugs. 2015 Jan;26(1):106-11. doi: 10.1097/CAD.0000000000000176.

PMID:
25280062
11.

Inferior vena cava filter usage, complications, and retrieval rate in cancer patients.

Abtahian F, Hawkins BM, Ryan DP, Cefalo P, Nasser NJ, MacKay C, Jaff MR, Weinberg I.

Am J Med. 2014 Nov;127(11):1111-7. doi: 10.1016/j.amjmed.2014.06.025. Epub 2014 Jul 2.

PMID:
24997415
12.

Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy.

Nasser NJ, Wang Y, Borg J, Saibishkumar EP.

Brachytherapy. 2014 Jul-Aug;13(4):369-74. doi: 10.1016/j.brachy.2014.01.007. Epub 2014 Feb 20.

PMID:
24559795
13.

Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin.

Kundel Y, Nasser NJ, Purim O, Yerushalmi R, Fenig E, Pfeffer RM, Stemmer SM, Rizel S, Symon Z, Kaufman B, Sulkes A, Brenner B.

PLoS One. 2013 Jul 10;8(7):e68327. doi: 10.1371/journal.pone.0068327. Print 2013.

14.

Heparanase patents: dim past and bright future.

Nasser NJ, Nevo E.

Recent Pat Inflamm Allergy Drug Discov. 2013 May;7(2):162-7.

PMID:
23537141
15.

Lipid profile and serum characteristics of the blind subterranean mole rat, Spalax.

Nasser NJ, Kaplan M, Nevo E, Aviram M.

PLoS One. 2009;4(2):e4528. doi: 10.1371/journal.pone.0004528. Epub 2009 Feb 20.

16.

Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis.

Nasser NJ, Avivi A, Shafat I, Edovitsky E, Zcharia E, Ilan N, Vlodavsky I, Nevo E.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2253-8. doi: 10.1073/pnas.0812846106. Epub 2009 Jan 21.

17.

Factitious hyperamylasuria by a nurse: a symptom of Munchausen syndrome.

Nasser NJ, Israelit SH, Muhammad M, Basis F.

BMJ Case Rep. 2009;2009. pii: bcr10.2008.1070. doi: 10.1136/bcr.10.2008.1070. Epub 2009 May 8.

18.

Molecular structure of heparan sulfate from Spalax. Implications of heparanase and hypoxia.

Sandwall E, Bodevin S, Nasser NJ, Nevo E, Avivi A, Vlodavsky I, Li JP.

J Biol Chem. 2009 Feb 6;284(6):3814-22. doi: 10.1074/jbc.M802196200. Epub 2008 Dec 9.

19.

Candida parapsilosis septic arthritis in a renal transplant patient.

Masoud M, Nasser NJ, Karban A, Edelstein S.

J Clin Rheumatol. 2008 Feb;14(1):56. doi: 10.1097/RHU.0b013e318163ccec. No abstract available.

PMID:
18431105
20.

Heparanase involvement in physiology and disease.

Nasser NJ.

Cell Mol Life Sci. 2008 Jun;65(11):1706-15. doi: 10.1007/s00018-008-7584-6. Review.

PMID:
18425416

Supplemental Content

Loading ...
Support Center